Crystalline chemotherapeutic

Details Crystalline chemotherapeutic Crystalline chemotherapeutic

2011-08-09

2011-08-09

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S409000, C548S362100

Reexamination Certificate

active

07994208

ABSTRACT:
N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it is disclosed.

REFERENCES:
patent: 7297709 (2007-11-01), Dai et al.
patent: 2005/0020603 (2005-01-01), Dai et al.
patent: WO2004113304 (2004-12-01), None
patent: WO2007050574 (2007-05-01), None
U.S. Pharmacopoeia, pp. 1843-1884 (1995).
Dai, et al, “Discover of N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor”, J. Med. Chem., 50, 1584-1597 (2007).
International Search Report PCT, Jan. 19, 2009.
Aulton M.E., ed., Pharmaceutics: The Science of Dosage Form Design, 2nd Edition, Churchill Livingstone, 2004, Table of Contents.
Hilfiker R., ed., Polymorphism in the Pharmaceutical Industry, Wiley-VCH Verlag GmbH & Co., KGaA, Weinheim, Germany, 2006, Table of Contents.
Morris K.M., “Structural Aspects of Hydrate and Solvates,” Polymorphism in Pharmaceutical Solids, 1999, pp. 125-181.

Affiliated with

Also associated with

Rating

Crystalline chemotherapeutic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline chemotherapeutic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline chemotherapeutic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2621670